Lingsha Zhou

772 total citations
34 papers, 424 citations indexed

About

Lingsha Zhou is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Lingsha Zhou has authored 34 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 29 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Lingsha Zhou's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers), Acute Myeloid Leukemia Research (21 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Lingsha Zhou is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers), Acute Myeloid Leukemia Research (21 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Lingsha Zhou collaborates with scholars based in United States, Slovenia and Australia. Lingsha Zhou's co-authors include Srđan Verstovšek, Hagop M. Kantarjian, Jörge E. Cortes, Sherry Pierce, Prithviraj Bose, Naval Daver, Deborah A. Thomas, Naveen Pemmaraju, Elias Jabbour and Sherry Pierce and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Lingsha Zhou

34 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lingsha Zhou United States 12 377 344 214 138 16 34 424
Montse Gómez Spain 11 430 1.1× 270 0.8× 269 1.3× 215 1.6× 30 1.9× 16 467
Klaudia Bagienski Austria 4 319 0.8× 268 0.8× 200 0.9× 115 0.8× 15 0.9× 7 365
Rajmonda Fjerza Italy 5 620 1.6× 509 1.5× 364 1.7× 232 1.7× 13 0.8× 7 657
Elisa Rumi Italy 6 428 1.1× 323 0.9× 267 1.2× 140 1.0× 8 0.5× 10 443
Blanka Kubešová Czechia 3 245 0.6× 191 0.6× 142 0.7× 88 0.6× 12 0.8× 6 257
Peter A. te Boekhorst Netherlands 6 238 0.6× 225 0.7× 126 0.6× 94 0.7× 36 2.3× 8 331
Tymara Berry United States 8 171 0.5× 159 0.5× 116 0.5× 57 0.4× 29 1.8× 27 233
Virginia M. Zaleskas United States 6 309 0.8× 253 0.7× 173 0.8× 137 1.0× 71 4.4× 7 355
Yvonne Silber United Kingdom 6 218 0.6× 181 0.5× 183 0.9× 68 0.5× 20 1.3× 8 262
C Mannarelli Italy 3 240 0.6× 213 0.6× 157 0.7× 67 0.5× 4 0.3× 3 266

Countries citing papers authored by Lingsha Zhou

Since Specialization
Citations

This map shows the geographic impact of Lingsha Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingsha Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingsha Zhou more than expected).

Fields of papers citing papers by Lingsha Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingsha Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingsha Zhou. The network helps show where Lingsha Zhou may publish in the future.

Co-authorship network of co-authors of Lingsha Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Lingsha Zhou. A scholar is included among the top collaborators of Lingsha Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingsha Zhou. Lingsha Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arora, Sankalp, Jayastu Senapati, Lucia Masárová, et al.. (2024). Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).. Journal of Clinical Oncology. 42(16_suppl). 6572–6572. 1 indexed citations
2.
Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2023). The role of therapy in the outcome of patients with myelofibrosis. Cancer. 129(18). 2828–2835. 3 indexed citations
3.
Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2023). Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematologica. 146(6). 522–529. 1 indexed citations
4.
Bose, Prithviraj, Lucia Masárová, Naveen Pemmaraju, et al.. (2023). P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.. HemaSphere. 7(S3). e5738496–e5738496. 1 indexed citations
5.
Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2022). Improved survival of patients with myelofibrosis in the last decade: Single‐center experience. Cancer. 128(8). 1658–1665. 26 indexed citations
6.
Masárová, Lucia, Courtney D. DiNardo, Prithviraj Bose, et al.. (2021). Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Advances. 5(8). 2156–2164. 30 indexed citations
7.
Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2021). Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clinical Lymphoma Myeloma & Leukemia. 21(5). 318–327.e6. 11 indexed citations
8.
Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2020). Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 126(19). 4322–4331. 18 indexed citations
9.
Masárová, Lucia, Srđan Verstovšek, Jörge E. Cortes, et al.. (2018). Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood. 132(Supplement 1). 352–352. 6 indexed citations
10.
Pemmaraju, Naveen, Bing Z. Carter, Hagop M. Kantarjian, et al.. (2018). LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood. 132(Supplement 1). 687–687. 15 indexed citations
11.
Pemmaraju, Naveen, Bing Z. Carter, Hagop M. Kantarjian, et al.. (2017). Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood. 130. 256–256. 5 indexed citations
12.
Bose, Prithviraj, Naveen Pemmaraju, Kurt Schroeder, et al.. (2017). Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood. 130. 1632–1632. 2 indexed citations
13.
Bose, Prithviraj, Naval Daver, Naveen Pemmaraju, et al.. (2017). Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia. Blood. 130. 255–255. 21 indexed citations
14.
Strati, Paolo, Prithviraj Bose, Lindsey Lyle, et al.. (2017). Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Annals of Hematology. 96(5). 733–738. 9 indexed citations
15.
Bose, Prithviraj, Naval Daver, Elias Jabbour, et al.. (2016). Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood. 128(22). 478–478. 24 indexed citations
16.
Benton, Christopher B., Catherine Wilson, Sherry Pierce, et al.. (2015). Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leukemia Research. 39(4). 419–423. 8 indexed citations
17.
Cherry, Mohamad, Marylou Cárdenas-Turanzas, Hagop M. Kantarjian, et al.. (2013). Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leukemia Research. 37(11). 1472–1476. 4 indexed citations
18.
Daver, Naval, Aditi Shastri, Tapan M. Kadia, et al.. (2013). Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leukemia Research. 37(11). 1440–1444. 18 indexed citations
19.
Sever, Matjaž, Alfonso Quintás‐Cardama, Sherry Pierce, et al.. (2013). Significance of cytogenetic abnormalities in patients with polycythemia vera. Leukemia & lymphoma. 54(12). 2667–2670. 16 indexed citations
20.
Shastri, Aditi, Jörge E. Cortes, Elias Jabbour, et al.. (2012). A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia. Blood. 120(21). 1728–1728. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Montse Gómez Breakdown of academic impact, for papers by Klaudia Bagienski Breakdown of academic impact, for papers by Rajmonda Fjerza Breakdown of academic impact, for papers by Elisa Rumi Breakdown of academic impact, for papers by Blanka Kubešová Breakdown of academic impact, for papers by Peter A. te Boekhorst Breakdown of academic impact, for papers by Tymara Berry Breakdown of academic impact, for papers by Virginia M. Zaleskas Breakdown of academic impact, for papers by Yvonne Silber Breakdown of academic impact, for papers by C Mannarelli
Rankless by CCL
2026